Dopamine Agonist Market Size is valued at USD 1.4 billion in 2024 and is predicted to reach USD 2.9 billion by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.
Dopamine agonists are a class of drugs that imitate the effects of dopamine by activating dopamine receptors in the brain. They are mostly used to treat illnesses where dopamine plays a part in the disease process, such as Parkinson's disease, where dopamine levels are low. The growing incidence of Parkinson's disease, restless legs syndrome, and other neurological conditions that call for dopamine-modulating therapies is the main driver of the market. The occurrence of these disorders is predicted to rise as the world's population ages, which will increase demand even further. Furthermore, improvements in medication formulations, like transdermal and extended-release alternatives, improve patient compliance and increase market potential. The creation of new dopamine agonists with enhanced safety and efficacy profiles is also anticipated to propel market expansion.
However, the primary barriers to market expansion are the high expense of dopamine agonist therapy and the possibility of adverse effects like hallucinations and problems with impulse control. Moreover, the development of targeted medicines for Parkinson's disease and other dopamine-related illnesses, as well as the increased emphasis on precision medicine, provide market participants with substantial prospects. The development of healthcare infrastructure in developing nations is also anticipated to propel market expansion.
• Teva Pharmaceutical Industries Ltd
• GSK plc.
• Supernus Pharmaceuticals, Inc.
• Lundbeck A/S
• Amneal Pharmaceuticals LLC
• UCB Pharma
• Novartis AG
• VeroScience LLC.
• Pfizer Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Other Market Players
The Dopamine Agonist market is segmented based on drug, application, route of administration, and distribution channel. As per the drug, the market is segmented into Ergot Alkaloids and Non-Ergot Dopamine Agonists. By application, the market is segmented into Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia, and Others. By route of administration (ROA), the market is segmented into Oral, Injectable, and Others. The distribution channel category is further classified into Hospital Pharmacies, Retail Pharmacies, and Other Pharmacies.
The Non-Ergot Dopamine Agonists category is expected to hold a major global market share in 2021. Their enhanced safety profile explains this dominance, less likelihood of side effects associated with fibrosis, and great effectiveness in treating neurological conditions such as Parkinson's disease and restless legs syndrome (RLS). In contrast to its ergot-derived equivalents, non-ergot dopamine agonists, including pramipexole, ropinirole, rotigotine, and apomorphine have become widely used because of their better tolerability and lower risk of cardiovascular problems.
The use of dopamine agonists is being greatly influenced by the increasing prevalence of Parkinson's disease (PD), which is predicted to reach 1.2 million cases by 2030 in the United States, with 90,000 new diagnoses every year. Over 10 million individuals worldwide have Parkinson's disease (PD), the second most common neurological disease, with men 1.5 times more likely to develop it than women. The need for affordable treatments is highlighted by the economic burden, which is estimated to be USD 52 billion yearly in the United States and includes treatment, missed wages, and social security expenses. Given that the average annual cost of medications is USD 2,500, there is a growing need for long-acting, reasonably priced dopamine agonists, including generic versions, which is driving market growth.
The North American Dopamine Agonist market is expected to register the highest market share in revenue in the near future. Increases in hyperprolactinemia, Parkinson's disease, and restless legs syndrome (RLS) are driving market growth. Injectable and oral medications are examples of new drug formulations that are improving patient accessibility and compliance. The usage of ergot alkaloids and non-ergot dopamine agonists, as well as expanding biopharmaceutical research and regulatory approvals, are further factors propelling market expansion. Targeted medications are becoming more and more necessary, and hospital and retail pharmacies remain crucial distribution channels. In addition, Asia Pacific is projected to grow rapidly in the global Dopamine Agonist market because the burden of chronic diseases is growing, access to healthcare is improving, and investments in the biotech sector are growing. Increasing clinical studies, domestic medication production, and regulatory clearances are helping countries like China, India, and Japan lead this trend. Technological developments in injectable and oral medication delivery are also propelling industry expansion.
• August 2024: AbbVie Inc. acquired Cerevel Therapeutics, a clinical-stage biopharmaceutical business that specializes in neurological disorders, for USD 8.7 billion. By strengthening AbbVie's position in the neuroscience market, this acquisition may spur dopamine agonist therapy innovation and increase competition in neurological disease treatments.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Billion |
|
Revenue Forecast In 2034 |
USD 2.9 Billion |
|
Growth Rate CAGR |
CAGR of 7.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Drug, Application, Route Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Teva Pharmaceutical Industries Ltd, GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Dopamine Agonist Market By Drug-
• Ergot Alkaloids
• Non-Ergot Dopamine Agonists
Dopamine Agonist Market By Application-
• Parkinson's Disease
• Restless Legs Syndrome (RLS)
• Hyperprolactinemia
• Others
Dopamine Agonist Market By Route of Administration-
• Oral
• Injectable
• Others
Dopamine Agonist Market By Distribution Channel-
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies
Dopamine Agonist Market By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
